BB-301 for Muscular Dystrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial involves injecting BB-301 into the throat muscles of patients with OPMD to help them swallow better. The study focuses on patients who have already been monitored for a period of time. The goal is to see if the treatment is safe and effective.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is BB-301 safe for use in humans?
What makes the treatment BB-301 unique for muscular dystrophy?
BB-301 is a gene therapy that uses an adeno-associated virus (AAV) to deliver genetic material directly to muscle cells, which is different from traditional treatments that may not target the genetic cause of muscular dystrophy. This approach aims to address the underlying genetic defect, potentially offering a more effective and long-lasting solution.12367
What data supports the effectiveness of the treatment BB-301 for Muscular Dystrophy?
Research on similar AAV-based gene therapies shows promise in treating muscular dystrophies by effectively delivering genes to muscle cells, improving muscle function, and reducing symptoms in animal models. These studies suggest that AAV vectors can be engineered to enhance muscle targeting and gene delivery, which could be beneficial for treatments like BB-301.358910
Who Is on the Research Team?
Milan R. Amin, M.D.
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for individuals with Oculopharyngeal Muscular Dystrophy (OPMD) who have trouble swallowing (dysphagia) and have been part of a previous OPMD study for at least 6 months. Participants will undergo surgery under general anesthesia to receive the treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular dose of BB-301 injected into the pharyngeal muscles through an open surgical procedure under general anesthesia
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at multiple time points
Long-term follow-up
Long-term monitoring of adverse events for up to 15 years following dosing
What Are the Treatments Tested in This Trial?
Interventions
- BB-301
Find a Clinic Near You
Who Is Running the Clinical Trial?
Benitec Biopharma, Inc.
Lead Sponsor